

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-59 (canceled)

<sup>1</sup>  
Claim ~~60~~ (currently amended): A method for inhibiting  $\alpha_v\beta_3$  mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an  $\alpha_v\beta_3$  antagonist, wherein said antagonist is a matrix metalloproteinase polypeptide consisting of: ~~that includes an amino acid sequence shown in~~ SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.

Claims 61-64 (canceled)

<sup>2</sup>  
Claim ~~65~~ (previously presented): The method of claim ~~60~~<sup>1</sup> wherein said tissue is human tissue.

<sup>3</sup>  
Claim ~~66~~ (previously presented): The method of claim ~~65~~<sup>2</sup> wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

<sup>4</sup>  
Claim ~~67~~ (previously presented): The method of claim ~~66~~<sup>3</sup> wherein said tissue is arthritic.

<sup>5</sup>  
Claim ~~68~~ (previously presented): The method of claim ~~67~~<sup>4</sup> wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

Claim <sup>6</sup>~~6~~ (previously presented): The method of claim <sup>1</sup>~~6~~ wherein said tissue is the retinal tissue and said angiogenesis is retinal angiogenesis.

Claim <sup>7</sup>~~7~~ (previously presented): The method of claim <sup>6</sup>~~6~~ wherein said retinal tissue is in a patient with diabetic retinopathy or macular degeneration.

Claim <sup>8</sup>~~7~~ (previously presented): The method of claim <sup>1</sup>~~6~~ wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

Claim <sup>9</sup>~~7~~ (previously presented): The method of claim <sup>8</sup>~~7~~ wherein said tissue is a carcinoma.

Claim <sup>10</sup>~~7~~ (previously presented): The method of claim <sup>8</sup>~~7~~ wherein said solid tumor is a tumor of lung, pancreas, breast, colon, larynx or ovary.

Claim <sup>11</sup>~~7~~ (previously presented): The method of claim <sup>8</sup>~~7~~ wherein said administering is conducted in conjunction with chemotherapy.

Claim <sup>12</sup>~~7~~ (previously presented): The method of claim <sup>1</sup>~~6~~ wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

Claim <sup>13</sup>~~7~~ (previously presented): The method of claim <sup>1</sup>~~6~~ wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim <sup>14</sup>~~7~~ (previously presented): The method of claim <sup>1</sup>~~6~~ wherein said therapeutically effective amount is from about 0.1 mg/kg to about 300 mg/kg.

<sup>15</sup>  
Claim ~~78~~ (previously presented): The method of claim ~~60~~<sup>1</sup> wherein said administering comprises a single dose intravenously.

<sup>16</sup>  
Claim ~~79~~ (previously presented): The method of claim ~~60~~<sup>1</sup> wherein said administering comprises one or more dose administrations daily for one or more days.

<sup>17</sup>  
Claim ~~80~~ (previously presented): The method of claim ~~60~~<sup>1</sup> wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

<sup>18</sup>  
Claim ~~81~~ (previously presented): The method of claim ~~60~~<sup>1</sup> wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.




<sup>19</sup>  
Claim ~~82~~ (previously presented): The method of claim ~~60~~<sup>1</sup> wherein said angiogenesis is induced by a cytokine.



<sup>20</sup>  
Claim ~~83~~ (previously presented): The method of claim ~~82~~<sup>19</sup> wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor- $\alpha$  and epidermal growth factor.

<sup>21</sup>  
Claim ~~84~~ (previously presented): The method of claim ~~82~~<sup>19</sup> wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue angiogenesis.

Claims 85-87 (canceled)

<sup>22</sup>  
Claim ~~88~~ (currently amended): A method for inhibiting  $\alpha_v\beta_5$  mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an  $\alpha_v\beta_5$  antagonist, wherein said antagonist is an organic compound selected from the group consisting of compounds ~~7, 9, 10, 12, AND 14~~. represented by the following structures:





<sup>23</sup>  
Claim ~~89~~ (previously presented): The method of claim <sup>22</sup>~~88~~ wherein said tissue is human tissue.

<sup>24</sup>  
Claim ~~90~~ (previously presented): The method of claim <sup>23</sup>~~89~~ wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

<sup>25</sup>  
Claim ~~91~~ (previously presented): The method of claim <sup>22</sup>~~88~~ wherein said tissue is arthritic.

<sup>26</sup>  
Claim ~~92~~ (previously presented): The method of claim <sup>25</sup>~~91~~ wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

<sup>27</sup>  
Claim ~~93~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said tissue is the retinal tissue and said angiogenesis is retinal angiogenesis.

<sup>28</sup>  
Claim ~~94~~ (previously presented): The method of claim ~~93~~<sup>27</sup> wherein said retinal tissue is in a patient with diabetic retinopathy or macular degeneration.

<sup>29</sup>  
Claim ~~95~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

<sup>30</sup>  
Claim ~~96~~ (previously presented): The method of claim ~~95~~<sup>29</sup> wherein said tissue is a carcinoma.

<sup>31</sup>  
Claim ~~97~~ (previously presented): The method of claim ~~95~~<sup>29</sup> wherein said solid tumor is a tumor of lung, pancreas, breast, colon, larynx or ovary.

<sup>32</sup>  
Claim ~~98~~ (previously presented): The method of claim ~~95~~<sup>29</sup> wherein said administering is conducted in conjunction with chemotherapy.

<sup>33</sup>  
Claim ~~99~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

<sup>34</sup>  
Claim ~~100~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.

<sup>35</sup>  
Claim ~~101~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said therapeutically effective amount is from about 0.1 mg/kg to about 300 mg/kg.

<sup>36</sup>  
Claim ~~102~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said administering comprises a single dose intravenously.

<sup>37</sup>  
Claim ~~103~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said administering comprises one or more dose administrations daily for one or more days.

<sup>38</sup>  
Claim ~~104~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

<sup>39</sup>  
Claim ~~105~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.

<sup>40</sup>  
Claim ~~106~~ (previously presented): The method of claim ~~88~~<sup>22</sup> wherein said angiogenesis is induced by a cytokine.

<sup>41</sup>  
Claim ~~107~~ (previously presented): The method of claim ~~106~~<sup>40</sup> wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor- $\alpha$  and epidermal growth factor.

<sup>42</sup>  
Claim ~~108~~ (previously presented): The method of claim ~~106~~<sup>40</sup> wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue angiogenesis.